Formulation of Monoclonal Antibody Therapies
From Lab to Market
- 1st Edition - May 23, 2023
- Latest edition
- Author: Amal Ali Elkordy
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 3 6 5 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 4 2 8 - 0
Formulation of Monoclonal Antibody Therapies: From Lab to Market covers a wide range of topics about therapeutic monoclonal antibodies (mAbs) with a focus on formulation aspects.… Read more
Formulation of Monoclonal Antibody Therapies: From Lab to Market covers a wide range of topics about therapeutic monoclonal antibodies (mAbs) with a focus on formulation aspects. Therapeutic monoclonal antibodies are used for treatment of chronic diseases. It brings together a comprehensive knowledge in one accessible volume. Starting with foundational information on monoclonal antibodies, the book then discusses the importance of biopharmaceutical products, monoclonal antibodies, and biosimilars in treatment of chronic diseases, pharmaceutical aspects of mAbs, and how it can be administered. It also covers the industrial point of view and the clinical application of mAbs including in oncology, general medicine, rheumatology, hematology, dermatology, gastrointestinal tract, metabolic diseases, and dentistry. Formulation of Monoclonal Antibody Therapies: From Lab to Market is essential reading for researchers in biotechnology and biopharmaceutical fields, academics and pharmaceutical industrial scientists, and university students in pharmaceutical and biopharmaceutical sciences.
- Covers details of recent advances in using mAbs
- Examines how to overcome the challenges for formulations of therapeutic mAbs
- Includes clinical application of mAbs
Researchers in biotechnology/biopharmaceutical fields, academics and pharmaceutical industrial scientists, and advanced university students in pharmaceutical and biopharmaceutical sciences
1. Introduction about monoclonal antibodies
2. Biosimilar antibodies
3. Pharmaceutical aspects of mAbs: formulation, characterization, and current route of administration of monoclonal antibody therapies
4. Route of monoclonal antibodies administration
5. Industrial aspects of finished monoclonal antibody therapies
6. Application of approved and marketed products of monoclonal antibody therapies
2. Biosimilar antibodies
3. Pharmaceutical aspects of mAbs: formulation, characterization, and current route of administration of monoclonal antibody therapies
4. Route of monoclonal antibodies administration
5. Industrial aspects of finished monoclonal antibody therapies
6. Application of approved and marketed products of monoclonal antibody therapies
- Edition: 1
- Latest edition
- Published: May 23, 2023
- Language: English
AE
Amal Ali Elkordy
His research is on the areas of formulation of macromolecules, solid dosage forms, gene therapy, niosomal nano-particulate systems and enhancement of dissolution of poorly-water soluble drugs and has received several awards and presented work at several national and international conferences. Research outcomes are reachable to non-specialist audiences as well as to experts in the field of pharmaceutics and are recognised both nationally and internationally as evidenced from the significantly publish of over 130 publications, including journal articles and conference papers, most of which are published in high-impact journals and well-cited. Dr Elkordy has extensive teaching experience incorporating research findings as “Research informs Teaching”. He designed MSc Pharmaceutical and BioPharmaceutical Formulations which is one of the few courses in the UK covering biopharmaceuticals as well as pharmaceuticals.
Affiliations and expertise
Professor of Pharmaceutics, Faculty of Health Sciences and Wellbeing, School of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland, UKRead Formulation of Monoclonal Antibody Therapies on ScienceDirect